CD248 and neoplasm: Sustained antitumor response was observed in survival experiments using human neuroblastoma and Ewing sarcoma xenografts in nude mice, with complete reductions in tumor volumes and prolonged median survival of nearly 100 days compared to the admix control (anti-CD248 + MMAE separate) with median overall survival of 40–50 days in both cell lines.